Indolent lymphoma · 3 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Obinutuzumab monotherapy Variant #03 | — | R 166 941 | 21d | — | — | — | — | — |
Bendamustine and Obinutuzumab Variant #02 | — | R 106 233 | 28d | — | — | — | — | 2 |
Bendamustine monotherapy Variant #01 | — | R 5 419 | — | 13.8 mo | — | — | — | 1 |
3 of 3 regimens shown